Drug Trial Radar · NCT00883051
Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
Last checked: Nov 20, 2026Latest source record: Dec 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
512
Actual
Start
Jul 2009
Primary completion
Feb 2010
Study completion Feb 2010
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- CoLucid Pharmaceuticals
- First posted
- Apr 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.
Conditions
- Migraine Disorders
Interventions
LasmiditanDrug
Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Headache ResponseTime frame: 2 hours postdose
Locations
39 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Brussels, Belgium
Site not named
Liège, Belgium
Site not named
Montegnée, Liege, Belgium
Site not named
Hasselt, Limburg, Belgium
Site not named
Leuven, Vlaams-Brabant, Belgium
Site not named
Bruges, West-Vlaanderen, Belgium
Site not named
Helsinki, Etelä-Suomi, Finland
Site not named
Hyvinkää, Etelä-Suomi, Finland
Site not named
Mikkeli, Itä-Suomen Lääni, Finland
Site not named
Pori, Länsi-Suomen, Finland
Site not named
Jyväskylä, Länsi-Suomi, Finland
Site not named
Tampere, Länsi-Suomi, Finland
Site not named
Turku, Länsi-Suomi, Finland
Site not named
Paris, France
Site not named
Nice, Alpes-Maritimes, France
Site not named
Bordeaux, Gironde, France
Site not named
Toulouse, Haute-Garonne, France
Site not named
Lille, Nord, France
Site not named
Rouen, Seine-Maritime, France
Site not named
Berlin, Germany
Site not named
Bremen, Germany
Site not named
Hamburg, Germany
Site not named
Freiburg/Breisgau, Baden-Wurttemberg, Germany
Site not named
Göppingen, Baden-Wurttemberg, Germany
Site not named
München, Bavaria, Germany
Site not named
München, Bavaria, Germany
Site not named
Wiesbaden, Hesse, Germany
Site not named
Erkelenz, North Rhine-Westphalia, Germany
Site not named
Essen, North Rhine-Westphalia, Germany
Site not named
Münster, North Rhine-Westphalia, Germany
Site not named
Itzehoe, Schleswig-Holstein, Germany
Site not named
Seville, Andalusia, Spain
Site not named
Barcelona, Catalonia, Spain
Site not named
Santiago de Compostela, Galicia, Spain
Site not named
Alcorcón, Madrid, Spain
Site not named
Pamplona, Navarre, Spain
Site not named
Oviedo, Principality of Asturias, Spain
Site not named
Gandia, Valencia, Spain
Site not named
Valencia, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.